Royalty Pharma reported Q2 net income attributable to the company fell to $18M from $32M (-44%). Offsetting the weakness, adjusted EBITDA rose to $736M from $633M (+16%). Overall, results appear mixed, with weaker bottom-line offset by improved operating cash earnings.
Royalty Pharma reported Q2 net income attributable to the company fell to $18M from $32M (-44%). Offsetting the weakness, adjusted EBITDA rose to $736M from $633M (+16%). Overall, results appear mixed, with weaker bottom-line offset by improved operating cash earnings.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly negative
Sentiment Score
-0.12
Ticker Sentiment
